Loading...
XNAS
BBLGW
Market cap2mUSD
May 12, Last price  
13.50USD
Name

Bone Biologics Corp

Chart & Performance

D1W1MN
XNAS:BBLGW chart
No data to show
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
162.60%
Rev. gr., 5y
%
Revenues
0k
Net income
-7m
L-18.15%
-13,3430000-1,082,204-4,424,413-13,876,927-21,029,214-7,051,572-4,430,399-3,424,811-1,824,690-1,610,685695,933-8,948,731-7,324,924
CFO
-4m
L-56.83%
-24,326-4,871-45,451-5,6810-525,365-2,755,618-3,545,783-7,327,845-3,330,096-4,104,884-3,251,229-426,933-1,228,586-3,566,913-9,555,904-4,124,935
Earnings
Aug 07, 2025

Profile

Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBX is a combination product, which is an osteostimulative recombinant protein that provides target specific control over bone regeneration. It is developing NELL-1/DBX Fusion Device for spinal fusion procedures in skeletally mature patients with degenerative disc disease at one level from L4-S1. The company's platform technology has application in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. It has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. The company was founded in 2004 and is headquartered in Burlington, Massachusetts.
URL
https://www.bonebiologics.com/
IPO date
Nov 27, 2015
Employees
2
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
4,219
9,428
3,665
Unusual Expense (Income)
NOPBT
(4,219)
(9,428)
(3,665)
NOPBT Margin
Operating Taxes
(2,181)
Tax Rate
NOPAT
(4,219)
(9,428)
(1,485)
Net income
(7,325)
-18.15%
(8,949)
-1,385.86%
696
-143.21%
Dividends
(3,213)
Dividend yield
225.18%
Proceeds from repurchase of equity
2,616
5,044
4,430
BB yield
-183.39%
-424.10%
-184.93%
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
(3,325)
(3,027)
(7,538)
Cash flow
Cash from operating activities
(4,125)
(9,556)
(3,567)
CAPEX
Cash from investing activities
Cash from financing activities
4,423
5,044
4,430
FCF
(4,378)
(9,428)
(1,485)
Balance
Cash
3,325
3,027
7,538
Long term investments
Excess cash
3,325
3,027
7,538
Stockholders' equity
(85,018)
(80,908)
(71,945)
Invested Capital
88,502
83,815
77,109
ROIC
ROCE
EV
Common stock shares outstanding
1,517
263
48
Price
0.94
-79.20%
4.52
-91.02%
50.33
-94.04%
Market cap
1,427
19.95%
1,189
-50.35%
2,395
-85.02%
EV
(1,898)
(1,837)
(5,143)
EBITDA
(4,219)
(9,428)
(3,665)
EV/EBITDA
0.45
0.19
1.40
Interest
2,181
Interest/NOPBT